British-Swedish biopharma giant AstraZeneca, which manufactures the COVID-19 vaccine developed by scientists at the University of Oxford, on Thursday indicated that they would seek approval from the US medicines regulator for its jabs in the second half of this year. The AZD1222 vaccine, also being produced under licence by the Serum Institute of India (SII) as Covishield and approved for human use by the UK and European medicines regulators, is pending a US Food and Drug Administration (USFDA) application.As part of second-quarter financial results released on Thursday, which showed that the company and its sub-licensees including SII delivered more …
Related posts:
14th Round Of India-China Military Talks Fails On Outcome But Scores On Cordiality
CBI Arrests DSIIDC Sr Official, Private Person For Accepting Bribe Of Rs 1.70 Lakh
SBI Successfully Prices Its First International USD Denominated Public Bond For $300 Mn
Shipping congestion is growing at world’s biggest port
